Published in Clin Vaccine Immunol on December 22, 2010
Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol (2011) 1.03
Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep (2014) 0.96
Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol (2013) 0.95
Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. J Clin Immunol (2012) 0.91
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2013) 0.87
Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol (2015) 0.85
The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. Biochim Biophys Acta (2011) 0.82
Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology (2016) 0.80
Interleukin-12 family cytokines and sarcoidosis. Front Pharmacol (2014) 0.77
Solving the Conundrum: Immunogenetics of Sarcoidosis. Am J Respir Crit Care Med (2015) 0.75
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 60.35
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Sarcoidosis. N Engl J Med (2007) 14.92
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
Determination of lymphocyte division by flow cytometry. J Immunol Methods (1994) 11.48
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science (1995) 11.16
T cell activation. Annu Rev Immunol (2009) 7.40
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 6.83
Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 4.85
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med (1981) 4.02
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
T cell-dependent B cell activation. Annu Rev Immunol (1993) 3.81
A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med (2004) 3.33
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Immunologic abnormalities in sarcoidosis. Ann Intern Med (1980) 2.66
The immune paradox of sarcoidosis and regulatory T cells. J Exp Med (2006) 2.35
Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem (1997) 2.15
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood (2008) 2.15
TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol (2004) 2.11
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol (1993) 1.83
Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol (2003) 1.80
Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A (1996) 1.79
The infectious complications of sarcoidosis: a current perspective. Arch Intern Med (1976) 1.77
Heterogeneity of the circulating human CD4+ T cell population. Further evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells. J Immunol (1995) 1.74
The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol (2008) 1.72
Suppressor cell function in sarcoidosis. Ann Intern Med (1979) 1.65
The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol (1998) 1.53
T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol (2008) 1.52
Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol (1999) 1.41
Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest (1981) 1.41
Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev (2009) 1.38
Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol (1997) 1.34
Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev (2005) 1.32
Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol (1999) 1.30
RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol (1995) 1.29
Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol (2001) 1.25
Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol (1991) 1.23
Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol (2007) 1.22
T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr Opin Immunol (2004) 1.19
Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest (2005) 1.17
Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. J Biol Chem (1996) 1.15
Affordable CD4 T-cell enumeration for resource-limited regions: a status report for 2008. Cytometry B Clin Cytom (2008) 1.15
T cell-intrinsic requirement for NF-kappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response. J Immunol (2003) 1.14
Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med (2001) 1.12
The human gp39 promoter. Two distinct nuclear factors of activated T cell protein-binding elements contribute independently to transcriptional activation. J Biol Chem (1995) 1.12
CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med (2004) 1.12
Glucocorticoids attenuate T cell receptor signaling. J Exp Med (2001) 1.10
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun (1998) 1.10
Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One (2010) 1.09
Anergy in sarcoidosis: the role of interleukin-1 and prostaglandins in the depressed in vitro lymphocyte response. Clin Exp Immunol (1984) 1.09
Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax (1999) 1.02
Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells. J Immunol (1997) 1.02
Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun (2007) 1.01
Regulation of the interleukin-2 CD28-responsive element by NF-ATp and various NF-kappaB/Rel transcription factors. Mol Cell Biol (1997) 1.00
T cell antigen receptor signal transduction pathways. Cancer Surv (1996) 0.99
Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J Immunol (2008) 0.97
Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc (2007) 0.97
Treatment of sarcoidosis -- from a basic science point of view. J Intern Med (2003) 0.97
Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells: down-regulation upon myeloid differentiation. J Leukoc Biol (2004) 0.96
Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol (1998) 0.95
Sarcoidosis. Med Clin North Am (2005) 0.91
In vitro observations on sarcoid lymphocytes and their correlation with cutaneous energy and clinical severity of disease. Am Rev Respir Dis (1973) 0.91
Diminished levels of T cell receptor zeta chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum (1999) 0.90
Dexamethasone modulates TCR zeta chain expression and antigen receptor-mediated early signaling events in human T lymphocytes. Cell Immunol (2001) 0.83
Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J Rheumatol (2005) 0.82
Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz) (2007) 0.82
Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. Clin Exp Immunol (2006) 0.82
T cells in rheumatoid arthritis. Br J Rheumatol (1997) 0.76
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med (2006) 4.20
A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med (2004) 3.33
Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med (2013) 2.93
Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol (2012) 2.71
Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol (2003) 2.58
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis (2003) 2.49
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol (2002) 2.37
Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest (2007) 2.22
A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med (2010) 1.98
Cardiac sarcoidosis. Am Heart J (2008) 1.89
The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest (2008) 1.78
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
Cutaneous sarcoidosis. Semin Respir Crit Care Med (2010) 1.69
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest (2006) 1.50
Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Med (2012) 1.44
Treatment of sarcoidosis with infliximab. Chest (2005) 1.43
Chronic cutaneous lesions of sarcoidosis. Clin Dermatol (2007) 1.41
Neurosarcoidosis: presentations and management. Neurologist (2010) 1.33
Organizing pneumonia. Am J Med Sci (2008) 1.32
Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect Immun (2005) 1.24
Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol (2009) 1.23
Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun (2009) 1.19
A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.18
The etiologic agent of sarcoidosis: what if there isn't one? Chest (2003) 1.17
Spinal cord neurosarcoidosis. Am J Med Sci (2014) 1.17
The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.16
Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci (2007) 1.11
Health-related quality of life of persons with sarcoidosis. Chest (2004) 1.08
Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.07
Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest (2003) 1.06
Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med (2010) 1.05
Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol (2011) 1.03
Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics. Clin Chest Med (2006) 1.02
Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist (2012) 0.99
The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med (2003) 0.97
Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect Immun (2006) 0.96
Pancreatic pseudocyst rupture into the portal vein. South Med J (2009) 0.96
A new tool to assess sarcoidosis severity. Chest (2006) 0.95
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol (2011) 0.95
Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther (2013) 0.94
Successful treatment of lupus pernio with adalimumab. Arch Dermatol (2011) 0.94
Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci (2011) 0.93
Allergic bronchopulmonary aspergillosis. Clin Chest Med (2012) 0.91
Sarcoidosis. Med Clin North Am (2005) 0.91
Neurosarcoidosis. Curr Treat Options Neurol (2013) 0.90
Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med (2008) 0.89
Thalidomide for chronic sarcoidosis. Chest (2002) 0.88
Sarcoidosis presenting as bilateral vocal cord paralysis from bilateral compression of the recurrent laryngeal nerves from thoracic adenopathy. J Voice (2008) 0.87
Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med (2005) 0.87
Patient-reported outcome measures for sleep disorders and related problems: clinical and research applications. Chest (2013) 0.86
Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci (2010) 0.86
Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism. BMJ Case Rep (2013) 0.85
Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2002) 0.84
A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest (2013) 0.84
Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis. Am J Med Sci (2011) 0.84
Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J (2010) 0.83
Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol (2011) 0.83
Staple metalloptysis after lung resection for mycetoma: a case report and a review of the literature. Am J Med Sci (2008) 0.83
Pleural effusion caused by trapped lung. South Med J (2003) 0.83
Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol (2008) 0.83
Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest (2005) 0.83
Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest (2009) 0.82
Acute pulmonary exacerbations of sarcoidosis. Chest (2012) 0.82
Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis (2016) 0.81
Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology (2009) 0.81
Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature. Am J Med Sci (2007) 0.81
Quality of life evaluation in sarcoidosis: current status and future directions. Curr Opin Pulm Med (2008) 0.80
Bird-years as well as pack-years. Chest (2004) 0.80
High-dose-rate brachytherapy in combination with stenting offers a rapid and statistically significant improvement in quality of life for patients with endobronchial recurrence. Cancer J (2005) 0.79
Rapid development of sarcoid tenosynovitis. J Clin Rheumatol (2011) 0.79
Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J (2014) 0.79
Expanding the pool of healthcare providers to perform penicillin skin testing in the ICU. Intensive Care Med (2014) 0.79
The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.78
Small fiber neuropathy in sarcoidosis: Something beneath the surface. Respir Med (2010) 0.78
Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res (2013) 0.78
Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol (2012) 0.78
Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun (2012) 0.78
Highly active antiretroviral therapy for HIV with tuberculosis: pardon the granuloma. Chest (2002) 0.77
Vaginal involvement in a patient with sarcoidosis. Chest (2010) 0.77
Cardiac sarcoidosis: there is no instant replay. Chest (2005) 0.77
Analysis of differentially regulated mRNAs in monocytic cells induced by in vitro stimulation with Kveim-Siltzbach test reagent. Exp Lung Res (2004) 0.76
Severe hypersensitivity pneumonitis associated with anagrelide. Ann Pharmacother (2003) 0.76
A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res (2013) 0.76
Virus reactivation: a panoramic view in human infections. Future Virol (2011) 0.76
Reply to: Monogenic early-onset sarcoidosis is no longer a variant of "idiopathic" sarcoidosis. J Am Acad Dermatol (2013) 0.75
Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor. Crit Care Med (2010) 0.75
Sarcoidosis: lost in translation. Respirology (2011) 0.75
The authors reply. Crit Care Med (2014) 0.75
Tuberculous mediastinal lymphadenitis that evolved into pulmonary tuberculosis following transbronchial needle aspiration. Respirology (2010) 0.75
Chronic hypoxemia and paraganglioma: a rare case and discussion of potential mechanisms. Am J Med Sci (2014) 0.75
Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis. Nucl Med Commun (2016) 0.75
Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol (2010) 0.75
Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable. J Asthma (2012) 0.75
Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med (2014) 0.75